Kidney Transplantation Clinical Trial
Official title:
The Use of Campath-1H, Tacrolimus, and Sirolimus Followed by Sirolimus Withdrawal in Renal Transplant Patients
Transplant rejection occurs when a patient's body does not recognize the new organ and
attacks it. Patients who have kidney transplants must take drugs to prevent transplant
rejection. Alemtuzumab is a man-made antibody used to treat certain blood disorders. The
purpose of this study is to test the safety and effectiveness of using alemtuzumab in
combination with two other drugs, sirolimus and tacrolimus, to prevent organ rejection after
kidney transplantation. This study will also test whether this combination of medications
will allow patients to eventually stop taking antirejection medications entirely.
Study hypothesis: A new strategy of immunosuppression using alemtuzumab, tacrolimus, and
sirolimus for human renal transplantation will permit a step-wise withdrawal from
immunosuppressive drugs.
Drugs that suppress the immune system, such as sirolimus and tacrolimus, have contributed to
increased success of transplantation. However, to prevent organ rejection, transplant
recipients need to take immunosuppressive drugs for the rest of their lives, and these drugs
make patients more susceptible to infection, endangering their health and survival. Regimens
that are less toxic to or can eventually be withdrawn from transplant recipients are needed.
Alemtuzumab is a monoclonal antibody that binds to and depletes excess T cells in the bone
marrow of leukemia patients. This study will determine the effects of intravenous alemtuzumab
and oral sirolimus and tacrolimus after kidney transplantation. The study will also evaluate
this regimen's potential to allow eventual discontinuation of components of long-term
immunosuppressive therapy.
This study will last up to 4 years. Participants will undergo kidney transplantation on Day 0
and will receive intravenous doses of alemtuzumab, acetaminophen, and diphenhydramine on Days
0, 1, and 2, as well as methylprednisolone on Day 0. After transplant, patients will receive
up to 10 days of valganciclovir or acyclovir. Participants will take tacrolimus daily by
mouth for at least 60 days after transplant and sirolimus daily by mouth for at least 12
months after transplant. As part of opportunistic infection (OI) prophylaxis, participants
will also take sulfamethoxazole-trimethoprim by mouth 3 times a week, valganciclovir or
acyclovir for up to 10 days post-transplant, and clotrimazole or nystatin by mouth for at
least 3 months post-transplant.
There will be a minimum of 62 study visits spread out over 4 years after transplant. Vital
signs measurement, adverse event and OI reporting, medication history, physical exam, and
blood collection will occur at selected visits. Sirolimus withdrawal will begin when a
participant meets certain study criteria. The withdrawal process will occur over a minimum of
3 months at an approximate rate of 33% of the pre-withdrawal dose per month. Participants
eligible for sirolimus withdrawal will undergo several kidney biopsies, including one 2 weeks
prior to the start of withdrawal, 6 and 12 months after completion of withdrawal, 1 year
after study enrollment, and annually thereafter.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT01672957 -
ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil)
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 |